Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Molecular Oncology Gains Funds For R&D Operations

Premium

Framingham, Mass.--Genzyme Molecular Oncology, a Genzyme division that uses genomics, combinatorial chemistry, and other technologies to develop molecular approaches to cancer diagnosis and therapy, has announced the private placement of $20 million in 6 percent convertible debentures due in 2002. All purchasers were institutional investors. Proceeds will be used to fund the company's operations and R&D programs prior to an initial public offering. The debentures will be convertible into shares of Genzyme Molecular Oncology common stock at a discount to the market price at the time of conversion.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.